Linked Life Data

19070803

Source:http://linkedlifedata.com/resource/pubmed/id/19070803

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-12-16
pubmed:abstractText
Chemotherapy is the first line treatment for metastatic urothelial carcinoma. Cytotoxic drugs, in particular cisplatin-based, play an important role in the first line treatment of metastatic patients. Since the 80's, no drug association has done better than M-VAC (methotrexate, vinblastin, adriamycin et cisplatin) in terms of response rate and 5-year survival rate. The Gemcitabin-Cisplatin (GC) association gives less side effects with similar results. The use of G-CSF (granulocyte/colony stimulating factor) with M-VAC has led to propose a new schedule with dose intensification and better tolerance: M-VAC-HD. In 2008, GC and M-VAC-HD are the two recommended drug associations. Unfortunately, some patients cannot be treated with these toxic drugs, in particular because of Cisplatin toxicity for kidney function. Therefore it is important to continue research to improve tolerance and anti-tumoral efficacy. After failure of first line therapy no consensual drugs exist in the second line, ongoing trials and new agents should increase options in the future.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1166-7087
pubmed:author
pubmed:issnType
Print
pubmed:volume
18 Suppl 7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S261-76
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
[Metastases from urethelial carcinoma: role of chemotherapy].
pubmed:affiliation
Service d'Urologie, Hôpital Foch, Faculté de médecine Paris-Ile-de-France-Ouest, UVSQ, France. t.lebret@hopital-foch.org
pubmed:publicationType
Journal Article, English Abstract